TOP 5 MOST VIEWED ARTICLES

RECENT COMMENTS

Azmina: In my personal experience, Medical Oncology teams would love to be able to offer patients concurrent [...]   »Read more

Storme Guy: I agree that false promises or prediction are done in a non correct way. Always, medical oncologist [...]   »Read more

Alex: You use EUS for staging only the smaller tumours. What about using endoscopic mucosal resection for [...]   »Read more

dinha: Please write your comment here   »Read more

headcoverings for chemotherapy: I recently came across your blog and have been reading along. I thought I would leave my first c [...]   »Read more

 

Article type: Patient Voice

Keywords: fertility, fertility saving treatments, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Fertility: it’s up to doctors to think ahead

Fertility: it’s up to
doctors to think ahead

Young cancer patients should feel lucky to survive, and stop fussing about their prospects of having children. This attitude, though still widespread, is now being challenged by many patients and doctors, who argue that it is inexcusable to prescribe treatments that could render a patient infertile, without a thorough discussion of all the options.

» Emma Mason


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.